Efficacy, safety and biomarkers of SG001 for patients with previously treated recurrent or metastatic cervical cancer: an open-label, multicenter, phase Ib trial
1 Department of Gynecology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, P. R. China.
2 Department of Gynecology and Oncology, Beijing Obstetrics and Gynecology Hospital, Beijing, P. R. China.
3 Phase 1 Clinical Trial Center, Anning First People's Hospital, Anning, Yunnan, P. R. China.
4 Department of Oncology, The Second Hospital of Anhui Medical University, Hefei, Anhui, P. R. China.
5 Department of Oncology, The Second Affiliated Hospital of Kunming Medical University, Kunming, Yunnan, P. R. China.
6 Department of Oncology, First Affiliated Hospital of Gannan Medical University, Ganzhou, Jiangxi, P. R. China.
7 Department of Medical Oncology, The Second People's Hospital of Neijiang, Neijiang, Sichuan, P. R. China.
8 Department of Gynecology, Qilu Hospital of Shandong University, Jinan, Shandong, P. R. China.
9 Department of Rare and Head and Neck Oncology, Cancer Hospital of The University of Chinese Academy of Sciences Zhejiang Cancer Hospital, Hangzhou, Zhejiang, P. R. China.
10 Department of Gynecology, Henan Cancer Hospital, The Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, Henan, P. R. China.
11 Department of Gastroenterology and Urology, Hunan Cancer Hospital, Changsha, Hunan, P. R. China.
12 Department of Oncology, The Second People's Hospital of Hefei, Hefei, Anhui, P. R. China.
13 Department of Oncology, Heping Hospital Affiliated to Changzhi Medical College, Changzhi, Shanxi, P. R. China.
14 Clinical Development Division, CSPC Pharmaceutical Group Co., Ltd. Shijiazhuang, Hebei, P. R. China.